• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Best Read Articles on FDA Approvals in 2021

News
Article

The approval of the generic version of smoking-cessation drug Chantix (varenicline) garnered a lot of attention as did the OKs of Besremi (ropeginterferon alfa-2b-njft), a treatment for polycythemia vera, and Trudhesa (dihydroergotamine mesylate), a nasal spray for acute treatment of migraines.

FDA Approves Generic of Chantix, Pfizer's Smoking Cessation Drug

This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.

Read more

FDA Approves Treatment for Rare Blood Disease

Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

Read more

FDA Approves Therapy for Age-Related Blurry Vision

Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.

Read more

FDA Clears Novel Nasal Spray for Migraine

The therapy, to be launched in October, is delivered quickly to the bloodstream by targeting the upper nasal space.

Read more


FDA Approves Novel Therapy for Macular Degeneration

Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.

Read more

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.